- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05423899
Humanoid Robot vs Treatment as Usual for Loneliness
April 11, 2025 updated by: Soham Rej MD, MSc, Lady Davis Institute
Humanoid Robot Intervention vs Treatment as Usual For Loneliness in Long-term Care Homes
The investigators are aiming to compare the effects of a humanoid robot intervention to treatment as usual, on loneliness and mental health outcomes in older adults living in long-term care, through an assessor-blinded randomized controlled trial.
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Detailed Description
Seventy-four (n=74) older adults experiencing loneliness in 3 long-term care homes will be randomized 1:1 to an 8-week, twice a week social intervention with the Grace humanoid robot vs. a treatment as usual active control.
The investigators will assess change (baseline to week 8) in (1) loneliness (primary outcome), (2) depression severity and (3) stress (secondary outcomes), as well as (4) other exploratory outcomes : anxiety, quality of life and reduction in acute healthcare utilization.
The investigators will also assess the feasibility and acceptability of the intervention using qualitative methods.
Study Type
Interventional
Phase
- Not Applicable
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
60 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- living in a LTC home setting in Montreal
- cognitively healthy, mild cognitive impairment (MCI) or mild dementia (MMSE score of >20/clinical opinion of LTC homes staff members)
- able to provide consent
- loneliness UCLA-3 score of ≥ 6 or more (moderate-severe loneliness).
Exclusion Criteria:
- do not speak English
- inability to provide consent
- moderate to severe dementia (MMSE score <18/diagnosis of moderate-severe dementia/clinical opinion of LTC homes staff members)
- significant hearing loss
- acutely unstable medical illnesses, including delirium, acute cerebrovascular/cardiovascular events within the last 6 months; having a terminal medical diagnosis with prognosis of less than 12 months
- high suicide risk (e.g. active suicidal ideation and/or current/recent intent or plan).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Treatment as Usual
|
The treatment as usual active control group will not receive the robot intervention.
The investIgators have deliberately chosen the participating long-term care (LTC) homes due to their high frequency of social interactions for their clients as part of their routine care (e.g.
one-on-one and group activities, family interaction, exercise groups) compared to most LTC homes settings, making TAU an active control.
|
|
Experimental: Humanoid Robot
|
The Grace robot was designed by Awakening Health/Hanson Robotics for healthcare settings and to interact with the elderly and those isolated by the COVID-19 pandemic.
Grace is a robot with a human-like appearance, which can move, actively listen, engage in conversation and react appropriately to human emotions.
Intervention activities will mostly consist of active listening and general discussions about topics of interest (e.g.
hobbies, music).
The participant will also have the option of other types of interactions with the robot, including robot-led meditation, robot-led light exercise, listening to music and singing.
Because loneliness is a subjective experience and does not have a standardized solution, this is a personalized intervention approach.
We anticipate that each older adult participant will have different needs and wishes when interacting with the robot, which will allow for a more natural interaction with the robot.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in the University of California Los Angeles 3-item Loneliness Scale
Time Frame: Baseline and Week 8
|
Commonly-used validated scale to screen for loneliness.
Higher scores on this scale mean higher levels of loneliness.
|
Baseline and Week 8
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in the Perceived Stress Scale
Time Frame: Baseline and Week 8
|
14-item scale used to measure the degree to which life events are experienced and appraised as stressful.
Higher scores on this scale mean higher stress levels.
|
Baseline and Week 8
|
|
Patient Health Questionnaire
Time Frame: Baseline and Week 8
|
9-item self-report questionnaire used to diagnose depression and assess symptom severity.
Higher scores on this scale mean more symptoms of depression.
|
Baseline and Week 8
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Generalized Anxiety Disorder-7
Time Frame: Baseline and Week 8
|
Commonly-used validated scale to measure anxiety.
Higher scores on this scale mean more symptoms of anxiety.
|
Baseline and Week 8
|
|
EuroQoL-5 Dimensions
Time Frame: Baseline and Week 8
|
Commonly-used validated scale to measure quality of life.
Higher scores on this scale mean a better quality of life.
|
Baseline and Week 8
|
|
Change in acute healthcare utilization
Time Frame: Baseline and Week 8
|
Number of hospitalizations and emergency room visits between baseline and primary intervention endpoint.
|
Baseline and Week 8
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 1, 2022
Primary Completion (Actual)
March 1, 2023
Study Completion (Actual)
March 30, 2023
Study Registration Dates
First Submitted
June 1, 2022
First Submitted That Met QC Criteria
June 15, 2022
First Posted (Actual)
June 21, 2022
Study Record Updates
Last Update Posted (Actual)
April 16, 2025
Last Update Submitted That Met QC Criteria
April 11, 2025
Last Verified
October 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 427283
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
No IPD sharing plan
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
Massachusetts General HospitalRecruitingDepression | Depression - Major Depressive Disorder | Depression Chronic | Depression in Adults | Depression Disorders | Depression DisorderUnited States
-
University of California, San FranciscoNational Center for Complementary and Integrative Health (NCCIH)Active, not recruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
ProgenaBiomeWithdrawnDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Sorlandet Hospital HFUniversity of Oslo; Karolinska Institutet; Australian Catholic University; Helse...RecruitingAnxiety | Anxiety Depression | Depression Anxiety Disorder | Depression - Major Depressive DisorderNorway
-
Lipocine Inc.CompletedDepression, Postpartum | Postnatal Depression | Peripartum Depression | Depression, Post-Partum | Postpartum Depression (PPD) | Post-Natal DepressionUnited States
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Vituity PsychiatryActive, not recruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Kolby Walker, DO; Brittany KimbleRecruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
University of CincinnatiNational Center for Complementary and Integrative Health (NCCIH)RecruitingMild DepressionUnited States
-
Fondation FondaMentalGYNOVNot yet recruitingDepression | Depression in Adults | Depression DisorderFrance
Clinical Trials on Grace Robot
-
Johns Hopkins Bloomberg School of Public HealthNational Institute on Aging (NIA)RecruitingShared CareUnited States
-
Saint Joseph's University, PhiladelphiaRecruitingStroke | Cognitive Impairment | Cognitive Change | Neurological Injury | Activity, MotorUnited States
-
University of the Sciences in PhiladelphiaRecruitingStroke | Cognitive Change | Neuroplasticity | Dual Task | Exercise InterventionUnited States
-
University of Kansas Medical CenterUniversity of Missouri, Kansas CityCompleted
-
Massachusetts General HospitalPatient-Centered Outcomes Research Institute; Dartmouth-Hitchcock Medical Center and other collaboratorsRecruitingAging | Palliative Care | Multimorbidity | Preventive CareUnited States
-
Cedars-Sinai Medical CenterCompletedBreast Neoplasms | Neoplasm MetastasisUnited States
-
National Institute on Aging (NIA)Wishard Health Services; Nina Mason Pulliam Charitable TrustCompletedAging | Functional DeclineUnited States
-
Milton S. Hershey Medical CenterHospice Foundation of America; John and Wauna Harman FoundationCompletedTerminal Illness | Advance Care Planning | Advance Directives | Vulnerable PopulationsUnited States
-
University of Maryland, BaltimoreTerminatedStroke Sequelae | HemiparesisUnited States